RGD模体在肿瘤诊断与靶向治疗方面的研究现状  

Research status of the RGD motif in tumor diagnosis and targeted therapy

作　　者：毕建华[1] 崔艳花[2] 孙明忠[3] 刘淑清[2] 

机构地区：[1]大连医科大学,七年制2008级辽宁大连116044 [2]大连医科大学生物化学教研室,辽宁大连116044 [3]大连医科大学生物技术系,辽宁大连116044

出　　处：《国际病理科学与临床杂志》2012年第4期312-315,共4页Journal of International Pathology and Clinical Medicine

基　　金：国家自然科学基金(81171957;81272186);辽宁省高等学校杰出青年学者成长计划(LJQ2011094)~~

摘　　要：精氨酸-甘氨酸-天冬氨酸(arginyl-glycyl-aspartic acid,RGD)模体是一类含有RGD序列的短肽,有环形和线性两类,可以竞争性结合整合素受体,阻止肿瘤细胞与细胞外基质的黏附,还可以直接诱导肿瘤细胞凋亡,通过阻断整合素-斑点黏附激酶途径,抑制肿瘤细胞黏附、增殖、侵袭、转移。该类肽与整合素结合成为抗肿瘤药物设计的靶点。随着对其分子机制的深入研究,越来越多的含RGD模体的药物被运用于肿瘤的早期诊断和临床抗肿瘤的治疗。Arginyl-glycyl-aspartic acid（RGD） motif comprises a class of short,linear or cyclic peptides containing the RGD sequence,which can bind competitive to the integrin receptor and thus prevent the adhesion of tumor cells.RGD motif can lead to tumor cell apoptosis,and to the inhibition of tumor cell adhesion,proliferation,invasion,and metastasis by blocking the integrin-focal adhesion kinase（FAK） pathway.The binding site of RGD motif to integrin provides a target for designed anticancer drugs.As its molecular mechanism has been more clearly elucidated,an increasing number of drugs containing RGD motifs have been developed for the early diagnosis of tumors and for anti-tumor therapy.

关 键 词：RGD模体 肿瘤 分子影像 靶向治疗 

分 类 号：R730.5[医药卫生—肿瘤]